nintedanib and Retinal-Diseases

nintedanib has been researched along with Retinal-Diseases* in 1 studies

Other Studies

1 other study(ies) available for nintedanib and Retinal-Diseases

Article	Year
VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A Experimental eye research, 2020, Volume: 194 Various severe ocular diseases are associated with an elevated intravitreal expression of VEGF-A which increases the permeability of retinal endothelial cells (REC) or retinal pigment epithelial (RPE) cells in vivo and in vitro. Inhibition of VEGF receptor 2 (VEGFR2) is sufficient to completely prevent VEGF-A Topics: Blood-Retinal Barrier; Cell Movement; Cells, Cultured; Endothelial Cells; Humans; Indoles; Protein Kinase Inhibitors; Recovery of Function; Retinal Diseases; Tight Junctions; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2	2020

Article

Year

VEGF receptor 2 inhibitor nintedanib completely reverts VEGF-A

Experimental eye research, 2020, Volume: 194

Various severe ocular diseases are associated with an elevated intravitreal expression of VEGF-A which increases the permeability of retinal endothelial cells (REC) or retinal pigment epithelial (RPE) cells in vivo and in vitro. Inhibition of VEGF receptor 2 (VEGFR2) is sufficient to completely prevent VEGF-A

Topics: Blood-Retinal Barrier; Cell Movement; Cells, Cultured; Endothelial Cells; Humans; Indoles; Protein Kinase Inhibitors; Recovery of Function; Retinal Diseases; Tight Junctions; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2

2020